Neuren Pharmaceuticals Limited News - NEU | ADVFN

Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.

Get Started

Home
Investing
Stocks
Australia
ASX
Neuren Pharmaceuticals Limited (NEU)
Neuren Pharmaceuticals Limited (NEU) News

Neuren Pharmaceuticals Limited (NEU)

20.47

-0.05

(-0.24%)

Closed July 15 2:00AM

Delayed by 20 minutes

Professional-Grade Tools, for Individual Investors.

ACADIA Pharmaceuticals & Neuren Pharmaceuticals Announce Rare Pediatric Disease Designation for Trofinetide for the Treatment...

With No Approved Treatments in Rett Syndrome, FDA Decision Highlights Significant Unmet Need ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) and...

FDA Grants Orphan Drug Designation for Neuren's NNZ-2591 to Treat Angelman, Phelan-McDermid and Pitt Hopkins Syndromes

Neuren Pharmaceuticals (ASX: NEU) today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Neuren’s...

Positive Phase 2 Study Results of Trofinetide in Pediatric Rett Syndrome Published in Neurology, the Medical Journal of the A...

-- Statistically Significant Improvement Indicates Trofinetide’s Potential for Treating Rett Syndrome-- Trofinetide for Rett Syndrome has...

ACADIA Pharmaceuticals & Neuren Pharmaceuticals Announce Exclusive License Agreement for the North American Development & Com...

-ACADIA plans to initiate a Phase 3 study of trofinetide for the treatment of Rett syndrome, a rare neurodevelopmental congenital CNS...

American Stock Exchange to Trade Options on Five New Securities

NEW YORK, April 12 /PRNewswire/ -- The American Stock Exchange(R) (Amex(R)) will launch trading in options on Thursday, April 13, 2006 on the...

Neuren Pharmaceuticals

Delayed Upgrade Clock